Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Kürzel: NOV Forum: Aktien User: Coronaprofiteur

Die die Aktie heute runter geschossen haben, sind jetzt geknallt 🤣

Geil ihr 🍭…. Gibt mal wieder die 50€ her

500 stk; ek 45,60€

220 Stück. Aber auch EK 63

Bei mir auch 22%😄👍

Bin auch massiv rein über die letzten Wochen. Die Aktie macht knapp 30% meines Depots aus

Aber wie immer sachlich bleiben und alles beobachten

Bin gespannt ob uns die Tage ein schönes Weihnachtsgeschenkt beschert wird

Ich glaube der Durchbruch des Abwärtstrends ist gelungen , wir werden etwas Luft raus lassen die Tage und dann stetig nach oben steigen denke ich . Ein Glück hab ich meine Position aufgestockt

gerade 8% https://finance.yahoo.com/quote/NVO/

Nachblrslich angeblich bei + 11%

Fda hat wegovy Pille zugesagt

Bagsværd, Denmark, 22 December 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Wegovy® pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events*. The Wegovy® pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management. The approval is based on the OASIS trial programme and the SELECT trial2. In the OASIS 4 trial, oral semaglutide 25 mg taken once daily demonstrated 16.6% mean weight loss when treatment was adhered to in adult participants with obesity or overweight with one or more comorbidities1. The weight loss achieved with the Wegovy® pill is similar to that of injectable Wegovy® 2.4 mg. Furthermore, one in three people experienced 20% or greater weight loss in the OASIS 4 trial1. The well-known safety and tolerability profile of semaglutide was reaffirmed with the Wegovy® pill in the OASIS-4 trial, which was comparable to previous trials with semaglutide for weight management. “The pill is here. With today's approval of the Wegovy® pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy® injection,” said Mike Doustdar, president and CEO of Novo Nordisk. “As the first oral GLP-1 treatment for people living with overweight or obesity, the Wegovy® pill provides patients with a new, convenient treatment option that can help patients start or continue their weight loss journey. No other current oral GLP-1 treatment can match the weight loss delivered by the Wegovy® pill, and we are very excited for what this will mean for patients in the US”. Novo Nordisk expects to launch the Wegovy® pill in the US in early January 2026. Novo Nordisk has submitted oral semaglutide 25 mg once-daily for obesity to the European Medicines Agency (EMA) and other regulatory authorities during the second half of 2025. About the OASIS trial programme OASIS was a phase 3 clinical development programme with once-daily oral semaglutide 25 mg and 50 mg in obesity. The global clinical phase 3 programme consisted of four trials, enrolling approximately 1,300 adults with obesity or overweight with one or more comorbidities. OASIS 4 was a 64-week efficacy and safety phase 3b trial of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity or overweight with one or more comorbidities.

Die kommenden Wochen werden spannend. Euphorie bzw. Hoffnung und eventuell FOMO und Novo steht ganz schnell bei rund 60€

0.9% bei Lilly wow Wäre die News andersrum gekommen wäre Novo minimum 5% abgestürzt